Generalized Myasthenia Gravis (GMG) Managements Market
Rise in the prevalence of diseases, growing geriatric population and technological advancements are pushing the market growth
Generalized Myasthenia Gravis (GMG) Managements Market by Drug Type, End User, Region | Forecast 2023 to 2033
Generalized Myasthenia Gravis (GMG) Managements Market Snapshot (2023 to 2033)
The global Generalized Myasthenia gravis (GMG) market size is expected to surpass an impressive valuation of USD 1.32 Billion in 2023 and is projected to exhibit a compound annual growth rate (CAGR) of 7.6% from 2023 to 2033.
Generalized Myasthenia gravis (GMG) is an infrequent autoimmune disease that leads to skeletal muscle tiredness and weakness owing to antibodies that consequence interrupted interaction between muscles and nerves. With a geriatric population, the worldwide incidence of the disorder has risen over the past decade.
According to a National Library of Medicine report, the incidence of generalized myasthenia gravis (GMG) in the USA is 20 per 100,000 people. It has a female pervasiveness in those under 40 years old and a male primacy in those over 50 years old. Childhood MG is rare in Western populations but familiar in Asian nations, affecting approximately 50% of patients under the age of 15. According to reports, the disorder's prevalence appears to have risen in recent decades. This could be due to improved healthcare data, but diseases, in general, are becoming more common around the world.
Several organizations, authorities, and sectors are working to raise public and individual awareness of the disorder. For example, the Myasthenia Gravis Foundation of America (MGFA) is publicizing various ways to recognize June as Myasthenia Gravis Awareness Month. The foundation runs a publicity campaign in which they provide a 23-page toolkit and educate people about the ailment and available treatments. As an outcome, the patient population seeking treatment for the ailment expands.
|
Report Attribute |
Details |
|
Expected Market Value (2023) |
US$ 1.32 Billion |
|
Anticipated Forecast Value (2033) |
US$ 2.96 Billion |
|
Projected Growth Rate (2023 to 2033) |
7.6% CAGR |
Let us know your requirement to get
100% FREE customization
2017 to 2022 Generalized Myasthenia Gravis (GMG) Management Demand Analysis vs. Forecast 2023 to 2033
COVID-19 has had an unexpected and astounding global impact, with generalized myasthenia gravis (GMG) treatment suffering a detrimental effect throughout all regions during the disease outbreak. According to our assessment, the global market grew at a slower pace of 4.6% in 2020 than the average annual growth from 2017 to 2019. The sharp rise in CAGR is due to this industry's revenue and growth rate, which recovered to pre-pandemic stages once the pandemic was over.
The diagnosis proportion among people is rising as the disease's incidence and consciousness grow. As a consequence, the number of individuals requiring treatment is expanding. For instance, the global incidence of generalized myasthenia gravis (GMG) disorder is approximated to be 12.5 people per 100,000 people. Myasthenia gravis patients are on the rise, having more than doubled in the past 20 years. Prolonged innovation and research into new therapies with the patient populace's present unmet medical needs, is expected to lead to higher consumption of novel therapeutics over the projected timeframe.
Which are Some Prominent Drivers of the Generalized Myasthenia Gravis (GMG) Management Market?
The increased incidences of Myasthenia Gravis drive market growth
Globally, the disease's incidence has risen substantially in recent years. This rise could be attributed to increased disease awareness and diagnosis rates in both developed and developing nations. The nations' vastly improved reimbursement guidelines for the disorder are also cruising sales growth. Furthermore, based on a study conducted by the National Organization for Rare Disorders (NORD), the condition's prevalence in the United Kingdom is estimated to be 15 per 100,000 people, a figure that has risen over time. The popularity of novel therapeutic approaches is growing in tandem with the escalating diagnosis speed and favorable reimbursement guidelines for the ailment.
This is raising the attempts of the industry's prominent stakeholders to establish and obtain approval for novel drugs to treat the illness. For example, F. Hoffmann-La Roche Ltd has a drug in production for the treatment of generalized myasthenia gravis (GMG) called Enspyrng, with a filing date of 2024. During the forecast timeframe, these aspects are predicted to propel the market.
The growing geriatric population drives market expansion
The age structure of the population is another factor driving the market growth. As per Eurostat, more than one-fifth (20.8%) of the European population was estimated to be 65 or older in 2021. The proportion of people aged 80 and up in the EU population is predicted to more than double between 2021 and 2100, soaring from 6.0% to 14.6%. Based on the MDPI Journal of Clinical Medicine, the prevalence of the ailment rises progressively with age. The 60-89-year-old age group has the greatest incidence. As a result, the disease's prevalence is increasing as the population's average lifespan rises.
Based on a 2020 epidemiology of myasthenia gravis article posted by Value in Health Journal, the older population has a higher incidence of the ailment than younger ages. In the United Kingdom, for example, the pervasiveness of the disorder in the aging population was 46.4 per 100,000, in comparison to 12 per 100,000 in young adulthood.
Find your sweet spots for generating winning opportunities in this market.
Talk to AnalystWhat are the Challenges Projected to be Faced by the Market?
High treatment costs and insufficient reimbursement policies in emerging markets to stymie market growth
The elevated treatment costs and insufficient reimbursement policies in developing countries are predicted to stifle market sales growth. Based on the results of a recent survey of generalized myasthenia gravis (GMG) (MG) patients and their families, the financial burden of surviving the illness is substantial, as indicated by out-of-pocket payouts that are estimated more than USD 14,000 annually.
Region-Wise Insights
What Makes North America the Largest Market for Generalized Myasthenia Gravis (GMG) Management?
Rising incidence of the disease and the region's aging population drive market growth
In 2020, the North American market was worth USD 0.58 billion. The soaring incidence of the illness and the region's aging population are the contributing factors to market growth during the forecast period. Furthermore, the region's established healthcare facilities and favorable reimbursement policies are striving to improve diagnosis and therapy rates in both emerging and advanced economies. For instance, on September 6, 2022, the Myasthenia Gravis Foundation of America and the PAN Foundation revealed a new partnership to assist patients staying with generalized myasthenia gravis (GMG), providing up to USD 13,000 annually in financial help and other facilities to patients and their family members.
Another factor causing market revenue growth is the growing number of clinical trials and approvals. For example, on April 28, 2022, the USA Food and Drug Administration (FDA) authorized Ultomiris, a lengthy C5 complement inhibitor established by AstraZeneca, for the treatment of patients with generalized myasthenia gravis. As a result, the aforementioned factors are predicted to boost industry growth in the region throughout the forecast period.
Why is Asia Pacific Considered a Lucrative Region for the Generalized Myasthenia Gravis (GMG) Management Market?
Favorable reimbursement policies for treatment to drive the regional market
The Asia Pacific market revenues are anticipated to expand at a rapid rate during the forthcoming years, owing to the rising prevalence of generalized myasthenia gravis (GMG) and the availability of more favorable reimbursement policies for treatment, which is increasing the recurrence of diagnosis in addition to the number of people receiving treatment. For instance, Ultomiris (ravulizumab) was approved in Japan in August 2022 for the treatment of adult individuals with generalized myasthenia gravis (gMG) who have anti-acetylcholine receptor (AChR) antibodies and whose ailments are difficult to treat with elevated IVIg or plasmapheresis
Also, based on a 2020 study published in the Journal of the Formosan Medical Association in Australia, generalized myasthenia gravis (GMG) accounted for approximately 8.1% of the top ten indications for IVIg. These aspects are expected to propel the market's expansion in the region over the forecast period.
A unified Market Research Subscription Platform, built for today's disparate research needs.
Category-Wise Insights
By End-User, Which Segment is Projected to Lead the Market?
The growing number of hospital admissions has aided hospitals to dominate the industry in 2021
In 2021, the hospital segment held the lion's share. This is caused by a rise in hospitalizations and doctor visits. As a result of the side effects of the drugs, approximately 15-20% of patients develop a myasthenia crisis throughout their duration of treatment, necessitating hospitalization. Furthermore, the well-established medical infrastructure in industrialized economies is a factor driving this segment's expansion.
Which Drug Type Segment Will Generate High Revenue?
Monoclonal antibodies segment to grow rapidly owing to its potential efficacy
The monoclonal antibodies segment is expected to grow at a rapid rate throughout the forecast period, attributable to the disease's worldwide increased incidence and rising demand for particular therapeutics for its treatment. Tocilizumab, inebilizumab, rozanolixizumab, nipocalimab, satralizumab, and pozelimab are just a few of the monoclonal antibodies being studied for their potential efficacy as a treatment for generalized myasthenia gravis (GMG).
Market Competition
Key players in the Generalized Myasthenia Gravis (GMG) Management market are Alexion Pharmaceuticals, Argenx, UCB Biopharma, Horizon Therapeutics, Halozyme Therapeutics, Hoffmann-La Roche AG, Janssen Research & Development, LLC, Immunovant Sciences GmbH, Sanofi, Cartesian Therapeutics.
- Argenx declared the FDA's affirmation of its BLA filing for Efgartigimod for the treatment of generalized myasthenia gravis in March 2021.
- 2 Horizon Therapeutics plc acquired Viela Bio, Inc. in March 2021 with the goal of strengthening the portfolio, pipeline, and treatment emphasis on unique disease treatments.
Report Scope
|
Report Attribute |
Details |
|
Expected Market Value (2023) |
US$ 1.32 Billion |
|
Anticipated Forecast Value (2033) |
US$ 2.96 Billion |
|
Projected Growth Rate (2023 to 2033) |
7.6% CAGR |
|
Base Year for Estimation |
2022 |
|
Historical Data |
2017 to 2022 |
|
Forecast Period |
2023 to 2033 |
|
Quantitative Units |
Revenue in USD Billion and CAGR from 2023 to 2033 |
|
Report Coverage |
Revenue Forecast, Volume Forecast, Company Ranking, Competitive Landscape, Growth Factors, Trends, and Pricing Analysis |
|
Segments Covered |
|
|
Regions Covered |
|
|
Key Countries Profiled |
|
|
Key Companies Profiled |
Alexion Pharmaceuticals, Argenx, UCB Biopharma, Horizon Therapeutics, Halozyme Therapeutics, Hoffmann-La Roche AG, Janssen Research & Development, LLC, Immunovant Sciences GmbH, Sanofi, Cartesian Therapeutics |
|
Customization |
Available Upon Request |
Key Segments Profiled in the Generalized Myasthenia Gravis (GMG) Management Market Industry Survey
By Drug Types:
- Monoclonal Antibodies
- FcRn Inhibitors
- Corticosteroid
- Cholinesterase Inhibitors
- Pharmacotherapy
- Therapeutic Plasma Exchange
By End Users:
- Hospitals
- Specialty Clinics
- Others
By Region:
- North America
- Europe
- Asia Pacific
- Latin America
- Middle East and Africa (MEA)
Frequently Asked Questions
FMI projects the global Generalized Myasthenia Gravis (GMG) Management market to expand at a 7.6% value CAGR by 2033.
The global Generalized Myasthenia Gravis (GMG) Management market is estimated at a market value of US$ 1.32 Billion.
The global Generalized Myasthenia Gravis (GMG) Management market is expected to garner a market value of US$ 2.96 Billion.
FMI has projected North America to be one of the key regions for the Generalized Myasthenia Gravis (GMG) Management market.
Alexion Pharmaceuticals, Argenx, UCB Biopharma, Horizon Therapeutics, Halozyme Therapeutics, Hoffmann-La Roche AG, Janssen Research & Development, LLC, Immunovant Sciences GmbH, Sanofi, Cartesian Therapeutics.
Table of Content
1. Executive Summary | Generalized Myasthenia Gravis (GMG) Management Market
1.1. Global Market Outlook
1.2. Demand-side Trends
1.3. Supply-side Trends
1.4. Technology Roadmap Analysis
1.5. Analysis and Recommendations
2. Market Overview
2.1. Market Coverage / Taxonomy
2.2. Market Definition / Scope / Limitations
3. Market Background
3.1. Market Dynamics
3.1.1. Drivers
3.1.2. Restraints
3.1.3. Opportunity
3.1.4. Trends
3.2. Scenario Forecast
3.2.1. Demand in Optimistic Scenario
3.2.2. Demand in Likely Scenario
3.2.3. Demand in Conservative Scenario
3.3. Opportunity Map Analysis
3.4. Investment Feasibility Matrix
3.5. PESTLE and Porter’s Analysis
3.6. Regulatory Landscape
3.6.1. By Key Regions
3.6.2. By Key Countries
3.7. Regional Parent Market Outlook
4. Global Market Analysis 2018 to 2022 and Forecast, 2023 to 2033
4.1. Historical Market Size Value (US$ Million) Analysis, 2018 to 2022
4.2. Current and Future Market Size Value (US$ Million) Projections, 2023 to 2033
4.2.1. Y-o-Y Growth Trend Analysis
4.2.2. Absolute $ Opportunity Analysis
5. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033 By Treatment
5.1. Introduction / Key Findings
5.2. Historical Market Size Value (US$ Million) Analysis By Treatment, 2018 to 2022
5.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Treatment, 2023 to 2033
5.3.1. Drug Types
5.3.1.1. Monoclonal Antibodies
5.3.1.2. FcRn Inhibitors
5.3.1.3. Corticosteroids
5.3.1.4. Cholinesterase Inhibitors
5.3.2. Pharmacotherapy
5.3.3. Therapeutic Plasma Exchange
5.4. Y-o-Y Growth Trend Analysis By Treatment, 2018 to 2022
5.5. Absolute $ Opportunity Analysis By Treatment, 2023 to 2033
6. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033 By End Users
6.1. Introduction / Key Findings
6.2. Historical Market Size Value (US$ Million) Analysis By End Users, 2018 to 2022
6.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By End Users, 2023 to 2033
6.3.1. Hospitals
6.3.2. Specialty Clinics
6.3.3. Others
6.4. Y-o-Y Growth Trend Analysis By End Users, 2018 to 2022
6.5. Absolute $ Opportunity Analysis By End Users, 2023 to 2033
7. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033 By Region
7.1. Introduction
7.2. Historical Market Size Value (US$ Million) Analysis By Region, 2018 to 2022
7.3. Current Market Size Value (US$ Million) Analysis and Forecast By Region, 2023 to 2033
7.3.1. North America
7.3.2. Latin America
7.3.3. Europe
7.3.4. Asia Pacific
7.3.5. Middle East and Africa (MEA)
7.4. Market Attractiveness Analysis By Region
8. North America Market Analysis 2018 to 2022 and Forecast 2023 to 2033 By Country
8.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
8.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
8.2.1. By Country
8.2.1.1. United States of America
8.2.1.2. Canada
8.2.2. By Treatment
8.2.3. By End Users
8.3. Market Attractiveness Analysis
8.3.1. By Country
8.3.2. By Treatment
8.3.3. By End Users
8.4. Key Takeaways
9. Latin America Market Analysis 2018 to 2022 and Forecast 2023 to 2033 By Country
9.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
9.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
9.2.1. By Country
9.2.1.1. Brazil
9.2.1.2. Mexico
9.2.1.3. Rest of Latin America
9.2.2. By Treatment
9.2.3. By End Users
9.3. Market Attractiveness Analysis
9.3.1. By Country
9.3.2. By Treatment
9.3.3. By End Users
9.4. Key Takeaways
10. Europe Market Analysis 2018 to 2022 and Forecast 2023 to 2033 By Country
10.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
10.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
10.2.1. By Country
10.2.1.1. Germany
10.2.1.2. United Kingdom
10.2.1.3. France
10.2.1.4. Spain
10.2.1.5. Italy
10.2.1.6. Rest of Europe
10.2.2. By Treatment
10.2.3. By End Users
10.3. Market Attractiveness Analysis
10.3.1. By Country
10.3.2. By Treatment
10.3.3. By End Users
10.4. Key Takeaways
11. Asia Pacific Market Analysis 2018 to 2022 and Forecast 2023 to 2033 By Country
11.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
11.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
11.2.1. By Country
11.2.1.1. China
11.2.1.2. Japan
11.2.1.3. South Korea
11.2.1.4. Singapore
11.2.1.5. Thailand
11.2.1.6. Indonesia
11.2.1.7. Australia
11.2.1.8. New Zealand
11.2.1.9. Rest of Asia Pacific
11.2.2. By Treatment
11.2.3. By End Users
11.3. Market Attractiveness Analysis
11.3.1. By Country
11.3.2. By Treatment
11.3.3. By End Users
11.4. Key Takeaways
12. MEA Market Analysis 2018 to 2022 and Forecast 2023 to 2033 By Country
12.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
12.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
12.2.1. By Country
12.2.1.1. GCC Countries
12.2.1.2. South Africa
12.2.1.3. Israel
12.2.1.4. Rest of MEA
12.2.2. By Treatment
12.2.3. By End Users
12.3. Market Attractiveness Analysis
12.3.1. By Country
12.3.2. By Treatment
12.3.3. By End Users
12.4. Key Takeaways
13. Key Countries Market Analysis
13.1. United States of America
13.1.1. Pricing Analysis
13.1.2. Market Share Analysis, 2022
13.1.2.1. By Treatment
13.1.2.2. By End Users
13.2. Canada
13.2.1. Pricing Analysis
13.2.2. Market Share Analysis, 2022
13.2.2.1. By Treatment
13.2.2.2. By End Users
13.3. Brazil
13.3.1. Pricing Analysis
13.3.2. Market Share Analysis, 2022
13.3.2.1. By Treatment
13.3.2.2. By End Users
13.4. Mexico
13.4.1. Pricing Analysis
13.4.2. Market Share Analysis, 2022
13.4.2.1. By Treatment
13.4.2.2. By End Users
13.5. Germany
13.5.1. Pricing Analysis
13.5.2. Market Share Analysis, 2022
13.5.2.1. By Treatment
13.5.2.2. By End Users
13.6. United Kingdom
13.6.1. Pricing Analysis
13.6.2. Market Share Analysis, 2022
13.6.2.1. By Treatment
13.6.2.2. By End Users
13.7. France
13.7.1. Pricing Analysis
13.7.2. Market Share Analysis, 2022
13.7.2.1. By Treatment
13.7.2.2. By End Users
13.8. Spain
13.8.1. Pricing Analysis
13.8.2. Market Share Analysis, 2022
13.8.2.1. By Treatment
13.8.2.2. By End Users
13.9. Italy
13.9.1. Pricing Analysis
13.9.2. Market Share Analysis, 2022
13.9.2.1. By Treatment
13.9.2.2. By End Users
13.10. China
13.10.1. Pricing Analysis
13.10.2. Market Share Analysis, 2022
13.10.2.1. By Treatment
13.10.2.2. By End Users
13.11. Japan
13.11.1. Pricing Analysis
13.11.2. Market Share Analysis, 2022
13.11.2.1. By Treatment
13.11.2.2. By End Users
13.12. South Korea
13.12.1. Pricing Analysis
13.12.2. Market Share Analysis, 2022
13.12.2.1. By Treatment
13.12.2.2. By End Users
13.13. Singapore
13.13.1. Pricing Analysis
13.13.2. Market Share Analysis, 2022
13.13.2.1. By Treatment
13.13.2.2. By End Users
13.14. Thailand
13.14.1. Pricing Analysis
13.14.2. Market Share Analysis, 2022
13.14.2.1. By Treatment
13.14.2.2. By End Users
13.15. Indonesia
13.15.1. Pricing Analysis
13.15.2. Market Share Analysis, 2022
13.15.2.1. By Treatment
13.15.2.2. By End Users
13.16. Australia
13.16.1. Pricing Analysis
13.16.2. Market Share Analysis, 2022
13.16.2.1. By Treatment
13.16.2.2. By End Users
13.17. New Zealand
13.17.1. Pricing Analysis
13.17.2. Market Share Analysis, 2022
13.17.2.1. By Treatment
13.17.2.2. By End Users
13.18. GCC Countries
13.18.1. Pricing Analysis
13.18.2. Market Share Analysis, 2022
13.18.2.1. By Treatment
13.18.2.2. By End Users
13.19. South Africa
13.19.1. Pricing Analysis
13.19.2. Market Share Analysis, 2022
13.19.2.1. By Treatment
13.19.2.2. By End Users
13.20. Israel
13.20.1. Pricing Analysis
13.20.2. Market Share Analysis, 2022
13.20.2.1. By Treatment
13.20.2.2. By End Users
14. Market Structure Analysis
14.1. Competition Dashboard
14.2. Competition Benchmarking
14.3. Market Share Analysis of Top Players
14.3.1. By Regional
14.3.2. By Treatment
14.3.3. By End Users
15. Competition Analysis
15.1. Competition Deep Dive
15.1.1. Alexion Pharmaceuticals
15.1.1.1. Overview
15.1.1.2. Product Portfolio
15.1.1.3. Profitability by Market Segments
15.1.1.4. Sales Footprint
15.1.1.5. Strategy Overview
15.1.1.5.1. Marketing Strategy
15.1.2. Argenx
15.1.2.1. Overview
15.1.2.2. Product Portfolio
15.1.2.3. Profitability by Market Segments
15.1.2.4. Sales Footprint
15.1.2.5. Strategy Overview
15.1.2.5.1. Marketing Strategy
15.1.3. UCB Biopharma
15.1.3.1. Overview
15.1.3.2. Product Portfolio
15.1.3.3. Profitability by Market Segments
15.1.3.4. Sales Footprint
15.1.3.5. Strategy Overview
15.1.3.5.1. Marketing Strategy
15.1.4. Horizon Therapeutics
15.1.4.1. Overview
15.1.4.2. Product Portfolio
15.1.4.3. Profitability by Market Segments
15.1.4.4. Sales Footprint
15.1.4.5. Strategy Overview
15.1.4.5.1. Marketing Strategy
15.1.5. Halozyme Therapeutics
15.1.5.1. Overview
15.1.5.2. Product Portfolio
15.1.5.3. Profitability by Market Segments
15.1.5.4. Sales Footprint
15.1.5.5. Strategy Overview
15.1.5.5.1. Marketing Strategy
15.1.6. F. Hoffmann-La Roche AG
15.1.6.1. Overview
15.1.6.2. Product Portfolio
15.1.6.3. Profitability by Market Segments
15.1.6.4. Sales Footprint
15.1.6.5. Strategy Overview
15.1.6.5.1. Marketing Strategy
15.1.7. Janssen Research & Development, LLC
15.1.7.1. Overview
15.1.7.2. Product Portfolio
15.1.7.3. Profitability by Market Segments
15.1.7.4. Sales Footprint
15.1.7.5. Strategy Overview
15.1.7.5.1. Marketing Strategy
15.1.8. Immunovant Sciences GmbH
15.1.8.1. Overview
15.1.8.2. Product Portfolio
15.1.8.3. Profitability by Market Segments
15.1.8.4. Sales Footprint
15.1.8.5. Strategy Overview
15.1.8.5.1. Marketing Strategy
15.1.9. Sanofi
15.1.9.1. Overview
15.1.9.2. Product Portfolio
15.1.9.3. Profitability by Market Segments
15.1.9.4. Sales Footprint
15.1.9.5. Strategy Overview
15.1.9.5.1. Marketing Strategy
15.1.10. Cartesian Therapeutics
15.1.10.1. Overview
15.1.10.2. Product Portfolio
15.1.10.3. Profitability by Market Segments
15.1.10.4. Sales Footprint
15.1.10.5. Strategy Overview
15.1.10.5.1. Marketing Strategy
16. Assumptions & Acronyms Used
17. Research Methodology
Let us know your requirement to get
100% FREE customization
List of Tables
Table 1: Global Market Value (US$ Million) Forecast by Region, 2018 to 2033
Table 2: Global Market Value (US$ Million) Forecast by Treatment, 2018 to 2033
Table 3: Global Market Value (US$ Million) Forecast by End Users, 2018 to 2033
Table 4: North America Market Value (US$ Million) Forecast by Country, 2018 to 2033
Table 5: North America Market Value (US$ Million) Forecast by Treatment, 2018 to 2033
Table 6: North America Market Value (US$ Million) Forecast by End Users, 2018 to 2033
Table 7: Latin America Market Value (US$ Million) Forecast by Country, 2018 to 2033
Table 8: Latin America Market Value (US$ Million) Forecast by Treatment, 2018 to 2033
Table 9: Latin America Market Value (US$ Million) Forecast by End Users, 2018 to 2033
Table 10: Europe Market Value (US$ Million) Forecast by Country, 2018 to 2033
Table 11: Europe Market Value (US$ Million) Forecast by Treatment, 2018 to 2033
Table 12: Europe Market Value (US$ Million) Forecast by End Users, 2018 to 2033
Table 13: Asia Pacific Market Value (US$ Million) Forecast by Country, 2018 to 2033
Table 14: Asia Pacific Market Value (US$ Million) Forecast by Treatment, 2018 to 2033
Table 15: Asia Pacific Market Value (US$ Million) Forecast by End Users, 2018 to 2033
Table 16: MEA Market Value (US$ Million) Forecast by Country, 2018 to 2033
Table 17: MEA Market Value (US$ Million) Forecast by Treatment, 2018 to 2033
Table 18: MEA Market Value (US$ Million) Forecast by End Users, 2018 to 2033
Find your sweet spots for generating winning opportunities in this market.
Talk to AnalystList of Charts
Figure 1: Global Market Value (US$ Million) by Treatment, 2023 to 2033
Figure 2: Global Market Value (US$ Million) by End Users, 2023 to 2033
Figure 3: Global Market Value (US$ Million) by Region, 2023 to 2033
Figure 4: Global Market Value (US$ Million) Analysis by Region, 2018 to 2033
Figure 5: Global Market Value Share (%) and BPS Analysis by Region, 2023 to 2033
Figure 6: Global Market Y-o-Y Growth (%) Projections by Region, 2023 to 2033
Figure 7: Global Market Value (US$ Million) Analysis by Treatment, 2018 to 2033
Figure 8: Global Market Value Share (%) and BPS Analysis by Treatment, 2023 to 2033
Figure 9: Global Market Y-o-Y Growth (%) Projections by Treatment, 2023 to 2033
Figure 10: Global Market Value (US$ Million) Analysis by End Users, 2018 to 2033
Figure 11: Global Market Value Share (%) and BPS Analysis by End Users, 2023 to 2033
Figure 12: Global Market Y-o-Y Growth (%) Projections by End Users, 2023 to 2033
Figure 13: Global Market Attractiveness by Treatment, 2023 to 2033
Figure 14: Global Market Attractiveness by End Users, 2023 to 2033
Figure 15: Global Market Attractiveness by Region, 2023 to 2033
Figure 16: North America Market Value (US$ Million) by Treatment, 2023 to 2033
Figure 17: North America Market Value (US$ Million) by End Users, 2023 to 2033
Figure 18: North America Market Value (US$ Million) by Country, 2023 to 2033
Figure 19: North America Market Value (US$ Million) Analysis by Country, 2018 to 2033
Figure 20: North America Market Value Share (%) and BPS Analysis by Country, 2023 to 2033
Figure 21: North America Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033
Figure 22: North America Market Value (US$ Million) Analysis by Treatment, 2018 to 2033
Figure 23: North America Market Value Share (%) and BPS Analysis by Treatment, 2023 to 2033
Figure 24: North America Market Y-o-Y Growth (%) Projections by Treatment, 2023 to 2033
Figure 25: North America Market Value (US$ Million) Analysis by End Users, 2018 to 2033
Figure 26: North America Market Value Share (%) and BPS Analysis by End Users, 2023 to 2033
Figure 27: North America Market Y-o-Y Growth (%) Projections by End Users, 2023 to 2033
Figure 28: North America Market Attractiveness by Treatment, 2023 to 2033
Figure 29: North America Market Attractiveness by End Users, 2023 to 2033
Figure 30: North America Market Attractiveness by Country, 2023 to 2033
Figure 31: Latin America Market Value (US$ Million) by Treatment, 2023 to 2033
Figure 32: Latin America Market Value (US$ Million) by End Users, 2023 to 2033
Figure 33: Latin America Market Value (US$ Million) by Country, 2023 to 2033
Figure 34: Latin America Market Value (US$ Million) Analysis by Country, 2018 to 2033
Figure 35: Latin America Market Value Share (%) and BPS Analysis by Country, 2023 to 2033
Figure 36: Latin America Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033
Figure 37: Latin America Market Value (US$ Million) Analysis by Treatment, 2018 to 2033
Figure 38: Latin America Market Value Share (%) and BPS Analysis by Treatment, 2023 to 2033
Figure 39: Latin America Market Y-o-Y Growth (%) Projections by Treatment, 2023 to 2033
Figure 40: Latin America Market Value (US$ Million) Analysis by End Users, 2018 to 2033
Figure 41: Latin America Market Value Share (%) and BPS Analysis by End Users, 2023 to 2033
Figure 42: Latin America Market Y-o-Y Growth (%) Projections by End Users, 2023 to 2033
Figure 43: Latin America Market Attractiveness by Treatment, 2023 to 2033
Figure 44: Latin America Market Attractiveness by End Users, 2023 to 2033
Figure 45: Latin America Market Attractiveness by Country, 2023 to 2033
Figure 46: Europe Market Value (US$ Million) by Treatment, 2023 to 2033
Figure 47: Europe Market Value (US$ Million) by End Users, 2023 to 2033
Figure 48: Europe Market Value (US$ Million) by Country, 2023 to 2033
Figure 49: Europe Market Value (US$ Million) Analysis by Country, 2018 to 2033
Figure 50: Europe Market Value Share (%) and BPS Analysis by Country, 2023 to 2033
Figure 51: Europe Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033
Figure 52: Europe Market Value (US$ Million) Analysis by Treatment, 2018 to 2033
Figure 53: Europe Market Value Share (%) and BPS Analysis by Treatment, 2023 to 2033
Figure 54: Europe Market Y-o-Y Growth (%) Projections by Treatment, 2023 to 2033
Figure 55: Europe Market Value (US$ Million) Analysis by End Users, 2018 to 2033
Figure 56: Europe Market Value Share (%) and BPS Analysis by End Users, 2023 to 2033
Figure 57: Europe Market Y-o-Y Growth (%) Projections by End Users, 2023 to 2033
Figure 58: Europe Market Attractiveness by Treatment, 2023 to 2033
Figure 59: Europe Market Attractiveness by End Users, 2023 to 2033
Figure 60: Europe Market Attractiveness by Country, 2023 to 2033
Figure 61: Asia Pacific Market Value (US$ Million) by Treatment, 2023 to 2033
Figure 62: Asia Pacific Market Value (US$ Million) by End Users, 2023 to 2033
Figure 63: Asia Pacific Market Value (US$ Million) by Country, 2023 to 2033
Figure 64: Asia Pacific Market Value (US$ Million) Analysis by Country, 2018 to 2033
Figure 65: Asia Pacific Market Value Share (%) and BPS Analysis by Country, 2023 to 2033
Figure 66: Asia Pacific Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033
Figure 67: Asia Pacific Market Value (US$ Million) Analysis by Treatment, 2018 to 2033
Figure 68: Asia Pacific Market Value Share (%) and BPS Analysis by Treatment, 2023 to 2033
Figure 69: Asia Pacific Market Y-o-Y Growth (%) Projections by Treatment, 2023 to 2033
Figure 70: Asia Pacific Market Value (US$ Million) Analysis by End Users, 2018 to 2033
Figure 71: Asia Pacific Market Value Share (%) and BPS Analysis by End Users, 2023 to 2033
Figure 72: Asia Pacific Market Y-o-Y Growth (%) Projections by End Users, 2023 to 2033
Figure 73: Asia Pacific Market Attractiveness by Treatment, 2023 to 2033
Figure 74: Asia Pacific Market Attractiveness by End Users, 2023 to 2033
Figure 75: Asia Pacific Market Attractiveness by Country, 2023 to 2033
Figure 76: MEA Market Value (US$ Million) by Treatment, 2023 to 2033
Figure 77: MEA Market Value (US$ Million) by End Users, 2023 to 2033
Figure 78: MEA Market Value (US$ Million) by Country, 2023 to 2033
Figure 79: MEA Market Value (US$ Million) Analysis by Country, 2018 to 2033
Figure 80: MEA Market Value Share (%) and BPS Analysis by Country, 2023 to 2033
Figure 81: MEA Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033
Figure 82: MEA Market Value (US$ Million) Analysis by Treatment, 2018 to 2033
Figure 83: MEA Market Value Share (%) and BPS Analysis by Treatment, 2023 to 2033
Figure 84: MEA Market Y-o-Y Growth (%) Projections by Treatment, 2023 to 2033
Figure 85: MEA Market Value (US$ Million) Analysis by End Users, 2018 to 2033
Figure 86: MEA Market Value Share (%) and BPS Analysis by End Users, 2023 to 2033
Figure 87: MEA Market Y-o-Y Growth (%) Projections by End Users, 2023 to 2033
Figure 88: MEA Market Attractiveness by Treatment, 2023 to 2033
Figure 89: MEA Market Attractiveness by End Users, 2023 to 2033
Figure 90: MEA Market Attractiveness by Country, 2023 to 2033
Need specific information?
Request CustomizationExplore Healthcare Insights
View Reports
